Combination therapies in multiple myeloma show superior efficacy over monotherapies, with higher response rates and progression-free survival. Monotherapy with agents like Empliciti and Darzalex shows ...

In an interview with CURE, Craig Hofmeister provided insight into the potential for combination regimens in relapsed/refractory patients with multiple myeloma. Findings from early clinical trials are ...

At the 57th annual meeting of the American Society of Hematology, oncologists discussed trial data evaluating combination therapies for multiple myeloma and lymphoma. In a session on new agents and ...

Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.

MISSISSAUGA, ON, July 23, 2025 /CNW/ - GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with bortezomib and dexamethasone, or in ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...

Results from a subgroup analysis of the phase 3 ENDEAVOR study and a phase 2 study in diffuse large B cell lymphoma patients were presented at the annual meeting of the American Society of Hematology.